The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5454
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD ; volume:36 ; number:11 ; day:8 ; month:11 ; year:2021 ; pages:2192-2199 ; date:11.2022
Eye ; 36, Heft 11 (8.11.2021), 2192-2199, 11.2022
- Creator
-
Khan, Adnan H.
Pierce, Charles O.
De Salvo, Gabriella
Griffiths, Helen
Nelson, Marie
Cree, Angela J.
Menon, Geeta
Lotery, Andrew J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-021-01824-3
- URN
-
urn:nbn:de:101:1-2023010421112219617072
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Khan, Adnan H.
- Pierce, Charles O.
- De Salvo, Gabriella
- Griffiths, Helen
- Nelson, Marie
- Cree, Angela J.
- Menon, Geeta
- Lotery, Andrew J.
- SpringerLink (Online service)
Other Objects (12)
Choroidal remodeling following different anti-VEGF therapies in neovascular AMD
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
Combined inhibition of vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) for neovascular AMD in vitro
Pre-Clinical Studies of a Novel Bispecific Fusion Protein Targeting C3b and VEGF in Neovascular and Nonexudative AMD Models
Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
Gains in the current understanding of managing neovascular AMD with brolucizumab
Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion
Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents
The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
Evaluation of OCT biomarker changes in treatment-naive neovascular AMD using a deep semantic segmentation algorithm
Choroidal remodeling following different anti-VEGF therapies in neovascular AMD
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
Combined inhibition of vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) for neovascular AMD in vitro
Pre-Clinical Studies of a Novel Bispecific Fusion Protein Targeting C3b and VEGF in Neovascular and Nonexudative AMD Models
Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
Gains in the current understanding of managing neovascular AMD with brolucizumab
Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion
Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents
The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
Evaluation of OCT biomarker changes in treatment-naive neovascular AMD using a deep semantic segmentation algorithm
Choroidal remodeling following different anti-VEGF therapies in neovascular AMD
The architecture of macular neovascularizations predicts treatment responses to anti-VEGF therapy in neovascular AMD
Combined inhibition of vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) for neovascular AMD in vitro
Pre-Clinical Studies of a Novel Bispecific Fusion Protein Targeting C3b and VEGF in Neovascular and Nonexudative AMD Models
Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
Gains in the current understanding of managing neovascular AMD with brolucizumab
Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion
Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents
The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice